PDCD1 and neoplasm: Preclinical studies have shown that low-dose apatinib may upregulate PD-1 expression on tumor-infiltrating immune cells more effectively than full-dose apatinib, increase immune effector cell infiltration into tumors, and enhance the antitumor activity of PD-1 inhibitors (34, 35).